STAT1 and cancer: Increases in ROS, ERK1/2 and STAT1 confer resistance and poor survival outcomes in patients on cisplatin.57 However, STAT3, Bcl-2 and Bcl-xL are crucial for the survival of cancer cells and thus inhibition by both cisplatin and (possibly EGCG) could account for the lack of anticancer interference with EGCG.